Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic ductal adenocarcinoma is one of the most aggressive human malignancies, with
an overall 5-year survival rate of less than 4%. On the molecular level, an increasing number …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

No common malignancy is as rapidly and inevitably fatal as pancreatic ductal
adenocarcinoma (PDA). This grim fact has driven substantial research efforts into this …

Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical
resection is a requirement for a potential cure. However, the majority of patients are …

This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma
risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality,
despite significant improvements in diagnostic imaging and operative mortality rates. The 5 …

Deaths from pancreatic ductal adenocarcinoma, also known as pancreatic cancer, rank
fourth among cancer-related deaths in the United States, yet the causes of pancreatic cancer …

Background Pancreatic cancer has been and still is associated with a very poor prognosis.
This is due to a lack of major breakthroughs with respect to early diagnosis, prognostication …

Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer,
with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of …